Brainstorm Cell Therapeutics (BCLI) Competitors $2.28 +0.20 (+9.62%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BCLI vs. AFMD, OTLK, ANEB, VRCA, SRZN, IXHL, RAPT, RNXT, PMN, and LIANShould you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include Affimed (AFMD), Outlook Therapeutics (OTLK), Anebulo Pharmaceuticals (ANEB), Verrica Pharmaceuticals (VRCA), Surrozen (SRZN), Incannex Healthcare (IXHL), RAPT Therapeutics (RAPT), RenovoRx (RNXT), ProMIS Neurosciences (PMN), and LianBio (LIAN). These companies are all part of the "pharmaceutical products" industry. Brainstorm Cell Therapeutics vs. Affimed Outlook Therapeutics Anebulo Pharmaceuticals Verrica Pharmaceuticals Surrozen Incannex Healthcare RAPT Therapeutics RenovoRx ProMIS Neurosciences LianBio Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Affimed (NASDAQ:AFMD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and analyst recommendations. Does the MarketBeat Community favor BCLI or AFMD? Affimed received 148 more outperform votes than Brainstorm Cell Therapeutics when rated by MarketBeat users. Likewise, 70.24% of users gave Affimed an outperform vote while only 61.26% of users gave Brainstorm Cell Therapeutics an outperform vote. CompanyUnderperformOutperformBrainstorm Cell TherapeuticsOutperform Votes29161.26% Underperform Votes18438.74% AffimedOutperform Votes43970.24% Underperform Votes18629.76% Is BCLI or AFMD more profitable? Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Affimed's net margin of -7,836.26%. Brainstorm Cell Therapeutics' return on equity of 0.00% beat Affimed's return on equity.Company Net Margins Return on Equity Return on Assets Brainstorm Cell TherapeuticsN/A N/A -528.56% Affimed -7,836.26%-193.84%-107.24% Do analysts recommend BCLI or AFMD? Brainstorm Cell Therapeutics currently has a consensus target price of $30.00, suggesting a potential upside of 1,215.79%. Affimed has a consensus target price of $13.50, suggesting a potential upside of 1,034.45%. Given Brainstorm Cell Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Brainstorm Cell Therapeutics is more favorable than Affimed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Affimed 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media prefer BCLI or AFMD? In the previous week, Affimed had 14 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 14 mentions for Affimed and 0 mentions for Brainstorm Cell Therapeutics. Affimed's average media sentiment score of 0.42 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Affimed is being referred to more favorably in the news media. Company Overall Sentiment Brainstorm Cell Therapeutics Neutral Affimed Neutral Which has more volatility and risk, BCLI or AFMD? Brainstorm Cell Therapeutics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. Comparatively, Affimed has a beta of 2.06, suggesting that its stock price is 106% more volatile than the S&P 500. Do insiders & institutionals believe in BCLI or AFMD? 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. Comparatively, 30.8% of Affimed shares are owned by institutional investors. 6.7% of Brainstorm Cell Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Affimed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better valuation & earnings, BCLI or AFMD? Brainstorm Cell Therapeutics has higher earnings, but lower revenue than Affimed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBrainstorm Cell TherapeuticsN/AN/A-$17.19M-$4.80-0.48Affimed$877K21.85-$114.66MN/AN/A SummaryAffimed beats Brainstorm Cell Therapeutics on 9 of the 15 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Brainstorm Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCLI vs. The Competition Export to ExcelMetricBrainstorm Cell TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.00M$2.94B$5.13B$9.08BDividend YieldN/A1.90%4.91%4.22%P/E Ratio-0.4846.7391.4117.18Price / SalesN/A411.851,113.72116.79Price / CashN/A182.1042.7137.86Price / Book-1.903.894.794.78Net Income-$17.19M-$42.21M$120.07M$225.60M7 Day Performance57.24%-2.15%-1.92%-1.23%1 Month Performance83.87%4.20%11.46%3.36%1 Year Performance-21.24%18.39%30.49%16.59% Brainstorm Cell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCLIBrainstorm Cell Therapeutics3.9857 of 5 stars$2.28+9.6%$30.00+1,215.8%-21.7%$13.00MN/A-0.4840Gap UpHigh Trading VolumeAFMDAffimed4.4532 of 5 stars$2.14-0.5%$13.50+530.8%-68.5%$34.45M$8.95M0.0076Analyst RevisionNews CoverageOTLKOutlook Therapeutics1.8291 of 5 stars$1.45-2.0%$42.34+2,820.2%-82.8%$34.31MN/A0.0020ANEBAnebulo Pharmaceuticals1.9508 of 5 stars$1.30-7.1%$8.00+515.4%-52.9%$33.71MN/A-4.674News CoverageGap UpVRCAVerrica Pharmaceuticals4.6557 of 5 stars$0.73-4.5%$9.50+1,207.8%-87.7%$33.12M$5.12M-0.4240Analyst ForecastNews CoverageSRZNSurrozen1.086 of 5 stars$10.09+2.4%N/A+32.3%$32.79M$10M0.0042IXHLIncannex HealthcareN/A$1.83-1.6%N/A-54.1%$32.29M$86,000.00-1.343RAPTRAPT Therapeutics4.5209 of 5 stars$0.91+0.3%$9.50+941.2%-96.1%$31.90M$1.53M-0.3380RNXTRenovoRx1.2324 of 5 stars$1.27-1.1%$6.50+413.5%+76.1%$30.38MN/A-2.256Positive NewsGap UpPMNProMIS Neurosciences1.0717 of 5 stars$0.91-2.1%N/A-20.2%$29.75M$10,000.00-9.306Positive NewsLIANLianBioN/A$0.27flat$3.50+1,194.4%-94.2%$29.22MN/A-0.33110 Related Companies and Tools Related Companies AFMD Competitors OTLK Competitors ANEB Competitors VRCA Competitors SRZN Competitors IXHL Competitors RAPT Competitors RNXT Competitors PMN Competitors LIAN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BCLI) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainstorm Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
